StreetInsider.com News Articles

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 01 Jun 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to thirteen newly hired non-executive employees consisting of options to purchase an aggregate of 462,190 common shares of the Company (the "Options") with effective grant dates of May 18, 2026 and June 1, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the respective grant, and will vest

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 01 Jun 2026 16:01:00 -0400

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 01 Jun 2026 16:01:00 -0400

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 01 Jun 2026 16:01:00 -0400

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 21 May 2026 07:00:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT.

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 21 May 2026 07:00:00 -0400

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 21 May 2026 07:00:00 -0400

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 21 May 2026 07:00:00 -0400

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to

Form 8-K Definium Therapeutics, For: May 19

Tue, 19 May 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260519/26517284.html

Form 8-K Definium Therapeutics, For: May 19

Tue, 19 May 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260519/26517284.html

Form SCHEDULE 13G/A Definium Therapeutics, Filed by: Deep Track Capital, LP

Fri, 15 May 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26500631.html

Form SCHEDULE 13G/A Definium Therapeutics, Filed by: Deep Track Capital, LP

Fri, 15 May 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26500631.html

Form 8-K Definium Therapeutics, For: May 12

Tue, 12 May 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260512/26473581.html

Form 8-K Definium Therapeutics, For: May 12

Tue, 12 May 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260512/26473581.html

Definium begins second phase 3 trial of DT120 for depression

Tue, 12 May 2026 07:00:28 -0400

Definium Therapeutics (NASDAQ: DFTX) announced that the first patient has been dosed in Ascend, its second phase 3 study evaluating DT120 ODT for major depressive disorder treatment.

The study will evaluate the efficacy and safety of DT120 ODT versus placebo and is expected to enroll 175 participants in the United States. The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale score at week 6 between DT120 ODT 100 micrograms and placebo.